Evaluation of in-vivo and in-vitro binding property of a novel PET tracer for CSF1R imaging and comparison with two currently-used CSF1R-PET tracers

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background Colony-stimulating factor 1 receptor (CSF1R) is a promising imaging biomarker for neuroinflammation or tumor-associated macrophages. However, existing positron emission tomography (PET) tracers for CSF1R imaging commonly are suffering from limited specificity or sensitivity. Results We have performed 11 C-labeled radiosynthesis of compound FJRD (3-((2-amino-5-(1-methyl-1 H -pyrazol-4-yl)pyridin-3-yl)ethynyl)- N -(4-methoxyphenyl)-4-methylbenzamide) with excellent affinity for CSF1R and evaluated its in - vivo and in - vitro binding properties. PET images of [ 11 C]FJRD show low brain uptake and specific binding in the living organs except kidneys in the normal mice and rats. In - vitro autoradiographs show high-level specific binding in all investigated organs including brain, spleen, liver, kidneys and lungs when used self-blocking. Addition of cold CPPC partially blocked in - vitro [ 11 C]FJRD binding in the various organs with blocking effects from 9 to 67%, and other two CSF1R inhibitors, GW2580 and BLZ945, showed minimal blocking effect, suggesting unignorable off-target binding in these organs. Meanwhile specific bindings of [ 11 C]CPPC and [ 11 C]GW2580 were faint in the mouse organs except [ 11 C]CPPC specific binding detectable in the spleen. Conclusions These results suggest [ 11 C]FJRD as a potential CSF1R-PET tracer for more sensitively detecting CSF1R compared to [ 11 C]CPPC and [ 11 C]GW2580. However, high-level off-target binding requires further improvement in specificity for CSF1R imaging.

Article activity feed